EU evaluates arthritis drug to treat COVID-19 patients with pneumonia
Send a link to a friend
[July 19, 2021]
(Reuters) -The European medicines regulator
said on Monday it is evaluating an application to use arthritis drug,
Kineret, to treat COVID-19 in adult patients with pneumonia who are at
risk of developing severe respiratory failure.
|
|
 The European Medicines Agency (EMA) said it will assess data
including results from two ongoing clinical studies investigating
the safety and efficacy of the drug in patients hospitalised with
COVID-19.
Kineret, currently authorised to treat a number of inflammatory
conditions, is made by Swedish rare disease drug maker Sobi.
The drug reduces the activity of the immune system, and its active
substance blocks the activity of a chemical messenger in the immune
process that leads to inflammation.
[to top of second column] |
 "It is thought that this could also help reduce
the inflammation and tissue damage associated
with COVID-19," the EMA said, adding that it
expects the outcome from the evaluation in
October.
(Reporting by Yadarisa Shabong in Bengaluru;
Editing by Shailesh Kuber and Uttaresh.V)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
